Relapses/Refractory Non-Hodgkin Lymphoma - ImmunityBio

Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact

Patients & Caregivers
Healthcare Providers
Researchers
Our Company
News and Events
Investors

Select Page

Acceptance Requirements

Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma

Have completed two lines of chemotherapy

Search for:

Recent Posts

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
The Citizens Life Sciences Conference
2026 Jefferies Biotech on the Beach Summit
ImmunityBio Business Update and 2026 Financial Results

Please be aware of fraudulent activity by individuals, organizations, or websites that falsely claim to represent ImmunityBio in connection with clinical trial recruitment or commercial activities. Learn more

[Clinical Trials] We have an established process, governed by regulatory authorities, that is required for individuals seeking access to our Clinical Trials or approved therapies. Information on our trials is available directly through our Find a Clinical Trial page on our website or at the https://clinicaltrials.gov/website. ImmunityBio accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

[Recruitment activities] We have an established process required for all positions prior to issuing an offer of employment. The process requires formal interviews with members of our team and never requires payments or fees from job applicants. We do not conduct interviews via messaging tools like WhatsApp, Signal, etc. Qualified and interest candidates should apply to current openings directly through our careers page on the ImmunityBio website. ImmunityBio accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

In the event you receive a suspicious message – via email, WhatsApp, or text, etc. – we advise against providing any personal information or paying any fees. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the US Federal Bureau of Investigation (FBI) via www.ic3.gov.

Quicklinks

Pipeline
Careers
News and Events
Investors
Contact

Follow Us

 Facebook
 X
 LinkedIn

Legal

Privacy Policy
Legal Notice
Patent Notice

© 2026 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.